Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study

Home > Science Hub > Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study
Back to the list

November 16, 2023

You might also be interested by

News

CellCarta Secures Global Exclusivity for Biofidelity's Aspyre® Lung to Advance Targeted Lung Cancer Testing

March 18, 2026

More info

Posters

Validation of an ultra-sensitive assay for biomarker testing in NSCLC patients as Clinical Trial Assay (CTA)

March 3, 2026

More info

Posters

Challenging Hybrid Affinity Approach: Streamlined Total Antibody Quantitation with Uncompromised Sensitivity

March 3, 2026

More info

Posters

Patient-Centric Measurement of M-Protein Using High-Resolution Intact Mass Spectrometry

March 3, 2026

More info